RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors
Results from TRIDENT-1
Sherif, B., Besse, B., Solomon, B., Bazhenova, L., Kim, D. W., Lin, J. J., Wolf, J., Popat, S., Goto, K., De langen, A. J., Springfeld, C., Reynolds, M., Odom, D., Yuan, Y., Lee, A., Blum, S. I., Thamake, S., Ades, F., & Drilon, A. (2023). Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: Results from TRIDENT-1. Value in Health, 26(12), S484. Article PCR181. https://doi.org/10.1016/j.jval.2023.09.2619
